Projects
Identification of universal biomarkers of metastatic melanoma in CTCs KU Leuven
Cutaneous melanoma is the most aggressive form of skin cancer and is notorious for its high metastatic propensity. Melanoma cells disseminate by gaining access to the bloodstream, where they are detectable as Circulating Tumor Cells (CTCs), a subpopulation that constitutes the seeds for metastases and thereby responsible for the vast majority of melanoma-related deaths. The detection and analysis of CTCs can therefore assist early patient ...
Urine as a liquid biopsy for early stage cancer detection. University of Antwerp
A diaPASEF powered computational deep dive into the myotonic dystrophy type 1 liquid biopsy proteome Ghent University
Liquid biopsies have become increasingly important for disease diagnosis, but the focus has mainly been on nucleotides rather than proteins. Myotonic dystrophy type 1 (DM1) presents an opportunity to explore the use of protein analysis in liquid biopsies, as the disease causes significant tissue damage and protein leakage into blood. However, to achieve this, three challenges must be addressed: detecting low-abundance proteins, identifying ...
Analysis of plasma, platelets and urine nucleic acids: the value of liquid biopsy to improve diagnosis, follow-up and monitoring of treatment response of lung cancer and pancreatic cancer patients. University of Antwerp
Omics analysis in liquid biopsy samples of advanced tumours Ghent University
Molecular analysis of cell free circulating DNA (cfDNA) and/or circulating tumour cells (CTC) as 'liquid biopsy' for predictive biomarker assessment in patients with metastatic colorectal cancer (mCRC). University of Antwerp
Federated cloud-based Artificial Intelligence-driven platform for liquid biopsy analyses KU Leuven
Early prediction/detection of clinical response in metastatic NSCLC by improving liquid biopsy analysis KU Leuven
Non Small Cell Lung Cancer (NSCLC) patients are often treated with chemotherapy, which are toxic and can potentially lead to serious, even life-threatening side effects. Also, the quality of life can deteriorate. Unfortunately, not all patients respond to this treatment resulting in unnecessary treatment of these patients. Detecting the response at an early stage, preferably by a minimally or non-invasive alternative to tissue biopsies is ...
A metabolomics signature on liquid biopsy as a prognostic and predictive biomarker in early breast cancer KU Leuven
We will compare the metabolomics profile of large cohorts of breast cancer patients with documented treatment outcome in order to identify candidate biomarkers of treatment response or recurrence risk. Such identification fo non-responder patients and of patients at risk of relapse could help define those patients likely to benefit from neoadjuvant escalation treatment and those who might benefit from de-escalation strategies.